

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/705,743	11/11/2003	Hong Zhao	213.1143-CIP	4306	
7590 06/29/2006			EXAMINER		
MUSERLIAN, LUCAS & MERCANTI, LLP			CHISM, BILLY D		
15th Floor 475 Park Avenu	ie South	ART UNIT	PAPER NUMBER		
New York, NY 10016			1654		
			DATE MAILED: 06/29/2006	6	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applic	ation No.	Applicant(s)					
Office Action Summary		10/705	5,743	ZHAO ET AL.	ZHAO ET AL.				
		Exami	ner	Art Unit					
		B. Dell		1654					
Period fo	The MAILING DATE of this communi or Reply	cation appears on	the cover sheet	with the correspondence a	nddress				
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MANSIONS OF THE MANSIO	AILING DATE OF of 37 CFR 1.136(a). In no unication. tutory period will apply ar will, by statute, cause the	THIS COMMUN be event, however, may and will expire SIX (6) Ma application to become	NICATION. a reply be timely filed  ONTHS from the mailing date of this ABANDONED (35 U.S.C. § 133).					
Status									
1)□	Responsive to communication(s) file	d on							
2a)□	•	b)⊠ This action i	s non-final.						
3)[	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is								
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Disposit	ion of Claims								
4)⊠	4)⊠ Claim(s) <u>1-35</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5)	5) Claim(s) is/are allowed.								
6)□	6) Claim(s) is/are rejected.								
7)	Claim(s) is/are objected to.								
8)⊠	8) Claim(s) <u>1-35</u> are subject to restriction and/or election requirement.								
Applicat	on Papers								
9)[	The specification is objected to by the	Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority (	ınder 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:									
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.									
			·						
Attachmen	t(s)								
	e of References Cited (PTO-892)			Summary (PTO-413)					
	e of Draftsperson's Patent Drawing Review (P1 nation Disclosure Statement(s) (PTO-1449 or F			o(s)/Mail Date f Informal Patent Application (PT	O-152)				
	r No(s)/Mail Date	·	,						

Application/Control Number: 10/705,743

Art Unit: 1654

## **Detailed Action**

## Restriction/Election

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 3-9, 11-13, 16-18 and 20, drawn to methods of making the vancomycin-polymer conjugate, classified in class 514/2+, for example.
  - II. Claims 19, 22-29 and 35, drawn to vancomycin-polymer conjugate, classified in class 514/2+, for example.
  - III. Claims 33-34, drawn to methods of treating a mammal with a vancomycinpolymer conjugate, classified in class 514/2+, for example.

This application contains claims directed to the following patentably distinct species of Groups I-III, which are those vancomycin-polymer conjugate species of claims 1-2, 10, 14-15, 21, 30-32. The species are independent or distinct because the species are structurally and functionally different.

If Applicant elects either of Groups I, II, or III, Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-2, 10, 14-15, 21, 30-32 are generic, and these claims are related through dependency of claims.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Application/Control Number: 10/705,743 Page 3

Art Unit: 1654

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- 2. The inventions are independent or distinct because:
- 3. Inventions Group I and Group II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another materially different product or (2) that the product as claimed can be made by another materially different process (MPEP § 806.05(f)). In the instant case the methods of steps of reacting multiple components can be used to make many materially different compounds.
- 4. Inventions Group I and Group III are different method inventions requiring different method steps, requiring different reaction components and having different effects and end results.
- 5. Inventions Group II and Group III are related as product and method of using the product.

  These inventions are distinct wherein the methods can be used to treat mammals with structurally different compounds.
- 6. Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art in view of the variable classifications, restriction for examination purposes as indicated is proper.
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Art Unit: 1654

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Rejoinder

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. <u>All</u> claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to B. Dell Chism, whose telephone number is (571) 272-0962. The examiner can normally be reached on M-F 08:30 AM - 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on (571) 272-0562.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status

Application/Control Number: 10/705,743 Page 5

Art Unit: 1654

information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

\*\*\*

**BDC** 

B. DELL CHISM PATENT EXAMINER